Lifevantage Corp last reported quarterly results on Aug 27, 2026, for Q4 FY2026 (the quarter ended Jun 30, 2026): revenue of $42.4 million (-23.1% year over year) and diluted EPS of $0.10. It usually reports 35–58 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 3, 2026.
Results for Q1 FY2027, the quarter ending around Sep 30, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Nov 4, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–58 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 27, 2026
58 days after quarter end
|
Q4 FY2026
ended Jun 30, 2026
|
42
-23.1%
|
1
-34.7%
|
0.10
-32.3%
|
|
May 6, 2026
36 days after quarter end
|
Q3 FY2026
ended Mar 31, 2026
|
44
-25.2%
|
1
-60.7%
|
0.11
-57.7%
|
|
Feb 4, 2026
35 days after quarter end
|
Q2 FY2026
ended Dec 31, 2025
|
49
-27.8%
|
0
-89.2%
|
0.02
-89.5%
|
|
Nov 4, 2025
35 days after quarter end
|
Q1 FY2026
ended Sep 30, 2025
|
48
+0.7%
|
2
+18.0%
|
0.17
+21.4%
|
|
Sep 4, 2025
66 days after quarter end
|
Q4 FY2025
ended Jun 30, 2025
|
55
+12.6%
|
2
+50.1%
|
0.15
+49.2%
|
|
May 6, 2025
36 days after quarter end
|
Q3 FY2025
ended Mar 31, 2025
|
58
+21.1%
|
3
+109.2%
|
0.26
+100.0%
|
|
Feb 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Dec 31, 2024
|
68
+31.3%
|
3
+488.7%
|
0.19
+480.0%
|
|
Oct 29, 2024
29 days after quarter end
|
Q1 FY2025
ended Sep 30, 2024
|
47
-8.1%
|
2
+190.3%
|
0.14
+180.0%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LFVN (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Lehi, UT
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 849146
- Former names
- LIFELINE THERAPEUTICS, INC. (until Dec 6, 2006); YAAK RIVER RESOURCES INC (until Sep 28, 2004)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.